
Authors:

Mia J. Biondi^{1,2,3*}, Marjolein van Tilborg^{1,4*}, David Smookler^{1,2}, Gregory Heymann ¹, Analiza Aquino⁵, Stephen Perusini⁶, Erin Mandel^{1,2}, Robert A. Kozak⁷, Vera Cherepanov¹, Matthew Kowgier⁸, Bettina Hansen^{1,2}, Lee W. Goneau⁶, Harry L.A. Janssen^{1,2}, Tony Mazzulli^{5,6}, Gavin Cloherty⁹, Robert J. de Knegt⁴, Jordan J. Feld^{1,2,10}

SUPPLIMENTAL FIGURES AND TABLES

Supplementary Figure 1. Correlation between serum core-Ag and HCV-RNA from serum.



Supplementary Table 1. Cohort characteristics.

Baseline variable	n=117
Gender	
Male	69 (59.0%)
Female	48 (41.0%)
A	
Age	55.8 (± 11.7)
HCV Genotype	
1a	44 (37.6%)
1b	26 (22.2%)
1 (unspecified)	7 (6.0%)
2	9 (7.7%)
3	21 (17.9%)
4 5	4 (3.4%) 0
5 6	2 (1.7%)
Mixed genotype	3 (2.6%)
Unknown	1 (0.9%)
	(0.0,0)
Co-infection	
HBV	2 (1.7%)
115 (2 (1.170)
Cirrhosis	
Yes	33 (28.2%)
No	84 (71.8%)
	,
Treatment status	
Naïve	89 (76.1%)
Non-responder/treatment relapse	24 (20.5%)
Discontinued due to adverse events	4 (3.4%)

Supplementary Table 2. Concordance between DBS duplicates per condition and cut-off.

Test	-80°C	+4°C	+21°C	+37°C	+37°C/+4°C
HCV-Ab	67/68 (99%)	67/68 (99%)	67/68 (99%)	68/68 (100%)	66/68 (97%)
Core-Ag (Agreement > or <3 fmol/L)	67/68 (99%)	65/68 (96%)	66/68 (97%)	65/68 (96%)	66/68 (97%)
Core-Ag (Agreement > or <10 fmol/L)	66/68 (97%)	64/68 (94%)	66/68 (97%)	63/68 (93%)	66/68 (97%)

Supplementary Table 3. Sensitivity and specificity of HCV core antigen from DBS.

•	•	-		
Sample Type: DBS Number	HCV Core-Ag Qualitative	HCV Core-Ag Quantitative		
	Sensitivity >3fmol/L (95% CI) n=49	Sensitivity >10fmol/L (95% CI) n=49		
Venous:1	91.8% (84.2-99.5%)	87.8% (79.0-97.0%)		
Venous:2	93.9% (87.2-100%)	87.8% (79.0-97.0%)		
Finger-prick:1	91.8% (84.2-99.5%)	81.6% (70.8-92.5%)		
Finger-prick:1	93.9% (87.2-100%)	85.7% (75.9-95.5%)		